Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis.

ABSTRACT:

Objectives

Bempedoic acid (BA) is a novel oral low-density lipoprotein cholesterol lowering drug. This systematic review and meta-analysis aims to assess efficacy and safety for clinical outcomes in high cardiovascular (CV) risk patients.

Data sources

MEDLINE, Cochrane Central Register of Controlled Trials, Google Scholar, Embase, ClinicalTrials.gov, Clinical Trial Results and the American College of Cardiology web site were searched.

Study selection

Randomised controlled trials (RCTs) of BA versus placebo in high CV risk patients reporting clinical outcomes were included.

Main outcomes and measures

Primary efficacy outcomes were major adverse cardiovascular events (MACE), all-cause mortality, CV mortality and non-fatal myocardial infarction (MI). Safety outcom

SUBMITTER: Lin Y 

PROVIDER: S-EPMC8883220 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature